Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Information source: Dana-Farber Cancer Institute
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Squamous Cell Carcinoma; Carcinoma of Head/Neck
Intervention: Taxotere (Drug); Cisplatin (Drug); 5-Fluorouracil (Drug); Leucovorin (Drug); G-CSF (Drug); Ciprofloxacin (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Dana-Farber Cancer Institute Official(s) and/or principal investigator(s):
Marshall Posner, MD, Principal Investigator, Affiliation: Dana-Farber Cancer Institute
Summary
The purpose of this study is to further test a combination chemotherapy regimen for the
treatment of squamous cell carcinoma of the head and neck and to see if the addition of
supportive medicine can help reduce the side effects of these drugs.
Clinical Details
Official title: TPLF-4, Compressed TPLF for Locally Advanced Squamous Cell Carcinoma
Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: To evaluate the safety of a four day regimen of taxotere, cisplatin, 5-fluorouracil and high-dose leucovorin with growth factor support and ciprofloxacin.
Secondary outcome: To determine the efficacy of this regimen in patients with advances, previously untreated squamous cell carcinoma of the head and neck.
Detailed description:
- Patients will be admitted to hospital and receive a one hour infusion of taxotere.
Approximately 2 hours after taxotere is finished they will receive cisplatin,
5-fluorouracil, and leucovorin continuously over a 4 day period.
- Approximately 6-12 hours after the chemotherapy ends patients will be given growth
factor support and ciprofloxacin until the patient's ANC level is greater than 10,000.
- Infusion of chemotherapy will be repeated every 28 days (1 cycle is 28 days).
- During each cycle patients will have blood tests performed weekly and may be asked to
return to the Head and Neck Clinic for examination around the middle of each cycle.
- At the end of each cycle the impact of the chemotherapy will be assessed. If after 2
cycles, the cancer has not responded sufficiently the patient will not receive any more
chemotherapy. However, if significant reduction in the size of the patients tumor is
observed, a third and final cycle will be performed.
- During the fourth or fifth week of cycle 3, patients will undergo re-staging evaluation
under anesthesia with primary-site biopsies and planning of radiotherapy.
- Within 2 weeks of completion of chemotherapy cycle 3 all patients will receive twice
daily radiotherapy.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Histologic confirmation of squamous cell carcinoma of head and neck.
- All patients with previously untreated Stage III or IV.
- Measurable disease
- Complete recovery from previous diagnostic or therapeutic procedures.
- Life expectancy greater than 3 months
- Creatinine less than or equal to 1. 5
- SGOT less than 1. 5 x ULN
- Alkaline phosphatase less than 2. 5 x ULN
- WBC greater than or equal to 4,000/mm
- Platelet count greater than to equal to 100,000/mm
- Hemoglobin greater than or equal to 10gm/dl
- Patients of childbearing age must use effective contraception methods.
Exclusion Criteria:
- Patients with previous head and neck cancer except those treated with surgery only.
- Patients with concurrent malignancy of any site, except limited basal cell carcinoma
or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- Peripheral neuropathy exceeding grade 1.
- Cardiovascular or pulmonary disease
- Pregnant or breastfeeding women
Locations and Contacts
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information
Related publications: Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15;97(2):412-8. Colevas AD, Norris CM, Tishler RB, Lamb CC, Fried MP, Goguen LA, Gopal HV, Costello R, Read R, Adak S, Posner MR. Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am J Clin Oncol. 2002 Apr;25(2):153-9. Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May;132(5):526-31. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):678-81.
Starting date: January 1997
Ending date: December 2006
Last updated: June 2, 2008
|
